Abstract
Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system (CNS)
that is initiated and maintained by continuous migration of inflammatory immune cells
from the periphery into the target organ. However, in autoimmunity, migration of immune
cells is not only involved in the pathogenesis but also in the down-modulation of
the autoimmune attack, which is probably mediated by the infiltration of certain regulatory
immune cell populations inside the affected organs. The migratory activity of both
proinflammatory and regulatory leucocytes is controlled by chemokines and their receptors.
Thus, targeting the directed migration of immune cells and regulating leukocyte trafficking
across the blood-brain barrier (BBB) by means of modulation of chemokine signaling
receptors might open up new therapeutic avenues not only for MS but also for other
autoimmune diseases. In this review we summarize the chemotactic signaling pathways
known to be involved in neuroinflammation to date and the viability of these pathways
as targets for therapeutic strategies.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of the Neurological SciencesAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Role of chemokines in the regulation of Th1/Th2 and autoimmune encephalomyelitis.J Clin Immunol. 1999; 19: 273-279
- Neuronal damage in autoimmune neuroinflammation mediated by the death ligand TRAIL.Neuron. 2005; 46: 421-432
- Activation of microglial poly(ADP-ribose)-polymerase-1 by cholesterol breakdown products during neuroinflammation: a link between demyelination and neuronal damage.J Exp Med. 2003; 198: 1729-1740
- Axonal transection in the lesions of multiple sclerosis.N Engl J Med. 1998; 338: 278-285
- Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions.Ann Neurol. 2001; 50: 389-400
- The biology of chemokines and their receptors.Annu Rev Immunol. 2000; : 18217-18242
- The many roles of chemokines and chemokine receptors in inflammation.N Engl J Med. 2006; 354: 610-621
- Chemokines: a new classification system and their role in immunity.Immunity. 2000; 12: 121-127
- Chemokines as regulators of T cell differentiation.Nat Immunol. 2001; 2: 102-107
- Chemokine-based therapies for MS: how do we get there from here?.Trends Immunol. 2001; 22: 591-593
- Chemokines and chemokine receptors: potential therapeutic targets in multiple sclerosis.Curr Drug Targets Inflamm Allergy. 2004; 3: 279-290
- Chemokine receptors in the central nervous system: role in brain inflammation and neurodegenerative diseases.Brain Res Brain Res Rev. 2005; 48: 16-42
- Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research.Brain. 2006; 129: 1953-1971
- Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin.J Exp Med. 2003; 197: 725-733
- CNS-irrelevant T-cells enter the brain, cause blood-brain barrier disruption but no glial pathology.Eur J Neurosci. 2007; 26: 1387-1398
- Chemokine inhibition—why, when, where, which and how?.Biochem Soc Trans. 2004; 32: 366-377
- The expression and function of chemokines involved in CNS inflammation.Trends Pharmacol Sci. 2006; 27: 48-55
- Blockade of chemokine signaling in patients with multiple sclerosis.Neurology. 2006; 67: 1880-1883
- Chemokines in hematopoiesis.Curr Opin Hematol. 2008; 15: 49-58
- Cytokines and chemokines as regulators of angiogenesis in health and disease.Curr Pharm Des. 2006; 12: 3101-3115
- Chemokines and their receptors in the central nervous system.Front Neuroendocrinol. 2001; 22: 147-184
- Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1.Nature. 1996; 382: 635-638
- Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in C.Proc Natl Acad Sci U S A. 1998; 95: 9448-9453
- New developments in understanding and treating neuroinflammation.J Mol Med. 2008; (Jan 15. [Electronic publication ahead of print].)
- The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseases.Trends Neurosci. 2006; 29: 518-527
- Differential expression of chemokine receptors on peripheral blood, synovial fluid, and synovial tissue monocytes/macrophages in rheumatoid arthritis.Arthritis Rheum. 2001; 44: 1022-1032
- Chemokine receptor CCR5: insights into structure, function, and regulation.Cell Signal. 2004; 16: 1201-1210
- CCR1+/CCR5+ mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis.Am J Pathol. 2001; 159: 1701-1710
- Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients.J Clin Invest. 1999; 103: 807-815
- CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions.Proc Natl Acad Sci U S A. 1999; 96: 6873-6878
- Multiple sclerosis: a study of chemokine receptors and regulatory T cells in relation to MRI variables.Eur J Neurol. 2003; 10: 529-535
- Experimental autoimmune encephalomyelitis: CC chemokine receptor expression by trafficking cells.J Autoimmun. 2002; 19: 175-181
- Expression of chemokines RANTES, MIP-1alpha and GRO-alpha correlates with inflammation in acute experimental autoimmune encephalomyelitis.Neuroimmunomodulation. 1998; 5: 166-171
- Chemokine upregulation follows cytokine expression in chronic relapsing experimental autoimmune encephalomyelitis.Scand J Immunol. 2003; 58: 81-88
- Acute and relapsing experimental autoimmune encephalomyelitis are regulated by differential expression of the CC chemokines macrophage inflammatory protein-1alpha and monocyte chemotactic protein-1.J Neuroimmunol. 1998; 92: 98-108
- Selective CC chemokine receptor expression by central nervous system-infiltrating encephalitogenic T cells during experimental autoimmune encephalomyelitis.J Neurosci Res. 2001; 66: 705-714
- An important role for the chemokine macrophage inflammatory protein-1 alpha in the pathogenesis of the T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis.J Immunol. 1995; 155: 5003-5010
- Induction of experimental autoimmune encephalomyelitis in C57BL/6 mice deficient in either the chemokine macrophage inflammatory protein-1alpha or its CCR5 receptor.Eur J Immunol. 2000; 30: 1410-1415
- Amino-terminally modified RANTES analogues demonstrate differential effects on RANTES receptors.J Biol Chem. 1999; 274: 32478-32485
- Treatment of experimental autoimmune encephalomyelitis with the chemokine receptor antagonist Met-RANTES.J Neuroimmunol. 2002; 128: 16-22
- Leukocyte recruitment during onset of experimental allergic encephalomyelitis is CCR1 dependent.Eur J Immunol. 2000; 30: 2372-2377
- Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1.J Biol Chem. 2000; 275: 19000-19008
- Expression and characterization of the chemokine receptors CCR2 and CCR5 in mice.J Immunol. 2001; 166: 4697-4704
- The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE).Semin Immunol. 2003; 15: 23-32
- Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2.J Exp Med. 2000; 192: 1075-1080
- Experimental autoimmune encephalomyelitis (EAE) in CCR2(−/−) mice: susceptibility in multiple strains.Am J Pathol. 2003; 162: 139-150
- Absence of monocyte chemoattractant protein 1 in mice leads to decreased local macrophage recruitment and antigen-specific T helper cell type 1 immune response in experimental autoimmune encephalomyelitis.J Exp Med. 2001; 193: 713-726
- Transgenic expression of CCL2 in the central nervous system prevents experimental autoimmune encephalomyelitis.J Leukoc Biol. 2005; 77: 229-237
- Chemokine CCL2 and chemokine receptor CCR2 in early active multiple sclerosis.Eur J Neurol. 2004; 11: 445-449
- Frequent MRI study of a novel CCR2 antagonist in relapsing–remitting multiple sclerosis.Ann Neurol. 2007; 62: S74-S75
- A key role for CCR7 in establishing central and peripheral tolerance.Trends Immunol. 2007; 28: 274-280
- CXC chemokine ligand 13 plays a role in experimental autoimmune encephalomyelitis.J Immunol. 2006; 176: 7676-7685
- Expression of chemokine receptors CCR7 and CCR8 in the CNS during ChREAE.Scand J Immunol. 2007; 66: 383-392
- Lymphoid chemokines CCL19 and CCL21 are expressed in the central nervous system during experimental autoimmune encephalomyelitis: implications for the maintenance of chronic neuroinflammation.Brain Pathol. 2003; 13: 38-51
- CCL19 is constitutively expressed in the CNS, up-regulated in neuroinflammation, active and also inactive multiple sclerosis lesions.J Neuroimmunol. 2007; 190: 72-79
- Expression of CCR7 in multiple sclerosis: implications for CNS immunity.Ann Neurol. 2004; 55: 627-638
- CCR7 is required for the in vivo function of CD4 + CD25 + regulatory T cells.J Exp Med. 2007; 204: 735-745
- Distinctive role of CCR7 in migration and functional activity of naive- and effector/memory-like Treg subsets.Eur J Immunol. 2007; 37: 1575-1583
- Experimental autoimmune encephalomyelitis develops in CC chemokine receptor 7-deficient mice with altered T-cell responses.Scand J Immunol. 2006; 64: 361-369
- Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells.J Exp Med. 2001; 194: 847-853
- Characterization of CD4 + CD25 + natural regulatory T cells in the inflammatory infiltrate of human chronic periodontitis.J Leukoc Biol. 2008; 84: 311-318
- CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3 + regulatory T cells in gastric cancer.Int J Cancer. 2008; 122: 2286-2293
- Specific recruitment of regulatory T cells into the CSF in lymphomatous and carcinomatous meningitis.Blood. 2008; 111: 761-766
- D. CCR4-dependent regulatory T cell function in inflammatory bowel disease.J Exp Med. 2007; 204: 1327-1334
- CSF chemokine levels in relapsing neuromyelitis optica and multiple sclerosis.J Neuroimmunol. 2004; 149: 182-186
- Induction of macrophage-derived chemokine/CCL22 expression in experimental autoimmune encephalomyelitis and cultured microglia: implications for disease regulation.J Neuroimmunol. 2002; 130: 10-21
- IL4 gene delivery to the CNS recruits regulatory T cells and induces clinical recovery in mouse models of multiple sclerosis.Gene Ther. 2008; 15: 504-515
- Design, synthesis, and progress toward optimization of potent small molecule antagonists of CC chemokine receptor 8 (CCR8).J Med Chem. 2006; 49: 2669-2672
- CC chemokine receptor 8 in the central nervous system is associated with phagocytic macrophages.Am J Pathol. 2003; 162: 427-438
- Chemokine expression in murine experimental allergic encephalomyelitis.J Neuroimmunol. 1995; 58: 167-176
- Interactions between hemopoietically derived TNF and central nervous system-resident glial chemokines underlie initiation of autoimmune inflammation in the brain.J Immunol. 2002; 169: 7054-7062
- CXC chemokine receptors on human oligodendrocytes: implications for multiple sclerosis.Brain. 2005; 128: 1003-1015
- Expression of the chemokine receptors CXCR1 and CXCR2 in rat oligodendroglial cells.Brain Res Dev Brain Res. 2001; 128: 77-81
- Role for CXCR2 and CXCL1 on glia in multiple sclerosis.Glia. 2006; 53: 24-31
- CXC chemokine receptors expression during chronic relapsing experimental autoimmune encephalomyelitis.Ann N Y Acad Sci. 2000; : 917135-917144
- The Th17-ELR + CXC chemokine pathway is essential for the development of central nervous system autoimmune disease.J Exp Med. 2008; 205: 811-823
- CXCR3 signaling reduces the severity of experimental autoimmune encephalomyelitis by controlling the parenchymal distribution of effector and regulatory T cells in the central nervous system.J Immunol. 2007; 179: 2774-2786
- Chemokines in autoimmune diseases.Immunol Rev. 2000; : 17743-17751
- CXCR3 expression in human central nervous system diseases.Neuropathol Appl Neurobiol. 2001; 27: 127-138
- Expression of the interferon-gamma-inducible chemokines IP-10 and Mig and their receptor, CXCR3, in multiple sclerosis lesions.Neuropathol Appl Neurobiol. 2000; 26: 133-142
- Optic neuritis: chemokine receptor CXCR3 and its ligands.Br J Ophthalmol. 2004; 88: 1146-1148
- IP-10 and MCP-1 levels in CSF and serum from multiple sclerosis patients with different clinical subtypes of the disease.J Neurol Sci. 2002; 195: 41-46
- CXCL10 (IFN-gamma-inducible protein-10) control of encephalitogenic CD4+ T cell accumulation in the central nervous system during experimental autoimmune encephalomyelitis.J Immunol. 2001; 166: 7617-7624
- Induction of the genes for Cxcl9 and Cxcl10 is dependent on IFN-gamma but shows differential cellular expression in experimental autoimmune encephalomyelitis and by astrocytes and microglia in vitro.Glia. 2007; 55: 1728-1739
- Neutralization of IFN-inducible protein 10/CXCL10 exacerbates experimental autoimmune encephalomyelitis.Eur J Immunol. 2002; 32: 1784-1791
- IFN-inducible protein 10/CXC chemokine ligand 10-independent induction of experimental autoimmune encephalomyelitis.J Immunol. 2004; 172: 550-559
- Severe disease, unaltered leukocyte migration, and reduced IFN-gamma production in CXCR3−/− mice with experimental autoimmune encephalomyelitis.J Immunol. 2006; 176: 4399-4409
- CXCL12 limits inflammation by localizing mononuclear infiltrates to the perivascular space during experimental autoimmune encephalomyelitis.J Immunol. 2006; 177: 8053-8064
- A role for CXCL12 (SDF-1alpha) in the pathogenesis of multiple sclerosis: regulation of CXCL12 expression in astrocytes by soluble myelin basic protein.J Neuroimmunol. 2006; 177: 27-39
- Multiple roles of chemokine CXCL12 in the central nervous system: a migration from immunology to neurobiology.Prog Neurobiol. 2008; 84: 116-131
- Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment.Brain. 2006; 129: 200-211
- Pathological expression of CXCL12 at the blood-brain barrier correlates with severity of multiple sclerosis.Am J Pathol. 2008; 172: 799-808
- Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis.J Neuroimmunol. 2004; 148: 11-23
- A new class of membrane-bound chemokine with a CX3C motif.Nature. 1997; 385: 640-644
- Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses.J Clin Invest. 2001; 107: 1173-1181
- Control of microglial neurotoxicity by the fractalkine receptor.Nat Neurosci. 2006; 9: 917-924
- Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia.Proc Natl Acad Sci U S A. 1998; 95: 10896-10901
- CX3CL1 (fractalkine) and CX3CR1 expression in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis: kinetics and cellular origin.J Neuroinflammation. 2005; : 217
- Neuronal expression of fractalkine in the presence and absence of inflammation.FEBS Lett. 1998; 439: 203-207
- CX3CL1 and CX3CR1 expression in human brain tissue: noninflammatory control versus multiple sclerosis.J Neuropathol Exp Neurol. 2003; 62: 899-907
- CSF and serum levels of soluble fractalkine (CX3CL1) in inflammatory diseases of the nervous system.J Neuroimmunol. 2003; 137: 210-217
- Differential expression of the chemokine receptors CX3CR1 and CCR1 by microglia and macrophages in myelin-oligodendrocyte-glycoprotein-induced experimental autoimmune encephalomyelitis.Brain Pathol. 2003; 13: 617-629
- The neuronal chemokine CX3CL1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system.FASEB J. 2006; 20: 896-905
- Frequency of blood CX3CR1-positive natural killer cells correlates with disease activity in multiple sclerosis patients.FASEB J. 2005; 19: 1902-1904
Article info
Publication history
Accepted:
July 4,
2008
Received in revised form:
July 2,
2008
Received:
April 8,
2008
Identification
Copyright
© 2008 Elsevier B.V. Published by Elsevier Inc. All rights reserved.
